Smith Group Asset Management LLC Makes New Investment in IQVIA Holdings Inc. (NYSE:IQV)

Smith Group Asset Management LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,224 shares of the medical research company’s stock, valued at approximately $1,616,000.

Several other institutional investors have also modified their holdings of IQV. AQR Capital Management LLC increased its holdings in shares of IQVIA by 173.8% in the 2nd quarter. AQR Capital Management LLC now owns 90,689 shares of the medical research company’s stock valued at $19,175,000 after acquiring an additional 57,568 shares during the last quarter. Magnolia Capital Advisors LLC raised its holdings in IQVIA by 7.9% during the second quarter. Magnolia Capital Advisors LLC now owns 3,041 shares of the medical research company’s stock worth $643,000 after purchasing an additional 223 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of IQVIA by 4.8% during the 2nd quarter. NewEdge Advisors LLC now owns 20,119 shares of the medical research company’s stock worth $4,254,000 after buying an additional 918 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of IQVIA by 8.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 10,252 shares of the medical research company’s stock valued at $2,168,000 after buying an additional 795 shares during the last quarter. Finally, Quarry LP lifted its position in IQVIA by 272.9% in the second quarter. Quarry LP now owns 619 shares of the medical research company’s stock valued at $131,000 after acquiring an additional 453 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $203.59 on Wednesday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a 50-day simple moving average of $200.02 and a 200-day simple moving average of $221.09. The company has a market capitalization of $36.95 billion, a PE ratio of 26.72, a P/E/G ratio of 2.14 and a beta of 1.48.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IQV. Barclays cut their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.